ArticleBiomedical chromatography : BMC2025
A Method for Analysis of Free and Total Ropivacaine in Dog Plasma Using UHPLC-MS/MS.
Article in Biomedical chromatography : BMC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Method for Analysis of Free and Total Ropivacaine in Dog Plasma Using UHPLC-MS/MS.Biomedical chromatography : BMC · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ropivacaine is a local anesthetic commonly used in veterinary anesthesia. A liquid chromatography-mass spectrometry (LC-MS) method was developed to quantify free and total ropivacaine in dog plasma, which included rapid equilibrium dialysis. The method was validated for selectivity, specificity, matrix effect, calibration curve and range, accuracy and precision, carry-over, stability, and reinjection reproducibility according to the International Conference on Harmonization M10 guidelines. After ultra-high performance liquid chromatographic (UHPLC) separation, detection and quantification of ropivacaine was performed using a triple quadrupole tandem mass spectrometer with electrospray ionization. LC-MS method validation was carried out in a range of 0.05-1000 ng/mL ropivacaine in dog plasma in two dilutions (1:1 and 1:4). The precision and accuracy of the method were determined at four concentration levels and ranged from 0.40% to 5.30% and 85.50% to 113.30%, respectively. The lower limit of quantification was as low as 0.30 and 0.05 ng/mL, for the quantitation of protein-bound (1:4) and free (1:1) ropivacaine, respectively. All validation parameters met acceptance criteria. This UHPLC-MS/MS method was successfully applied in a clinical study that involved the intraperitoneal instillation of ropivacaine to anesthetized dogs and can be used to quantify free and total ropivacaine in dog plasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.